Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Salivary Gland Adenoid Cystic Carcinoma
share announcement

Salivary Gland Adenoid Cystic Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 17951

Special Issue Editor

Prof. Dr. Patrick Ha

E-Mail Website
Guest Editor
Department of Otolaryngology—Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA
Interests: salivary gland tumors; signaling pathways; gene fusions; promoter methylation; genome-wide analysis; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Salivary gland adenoid cystic carcinoma is a rare but progressive cancer that is prone to distant metastasis. Its behavior is unpredictable, and we currently lack good biomarkers to determine who is at risk for more aggressive disease. When recurrence or metastasis does occur, we do not have effective systemic therapies to offer. There are no known inciting factors, but the identification of novel gene fusions, with the oncogene Myb and the transcription factor NFIB, has stimulated interest in learning more about these significant events. Additional information about gene mutations and proteomic analysis has led to new avenues of translational exploration as well. With the growing body of literature on the pathways involved in carcinogenesis and clinical correlations, it is our hope that we can find novel pathways to target, identify novel therapeutics, and ultimately help patients afflicted with this deadly disease. For this Special Issue, we are soliciting basic, translational, and clinical research studies, as well as relevant review articles related to salivary gland adenoid cystic carcinoma.

Dr. Patrick Ha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adenoid cystic carcinoma
  • molecular studies
  • Myb–NFIB
  • gene fusion
  • genome-wide analysis
  • carcinogenesis
  • targeted therapy
  • clinical trials
  • biomarkers.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

10 pages, 1509 KiB  
Article
Multi-Class Cancer Subtyping in Salivary Gland Carcinomas with MALDI Imaging and Deep Learning
by David Pertzborn, Christoph Arolt, Günther Ernst, Oliver J. Lechtenfeld, Jan Kaesler, Daniela Pelzel, Orlando Guntinas-Lichius, Ferdinand von Eggeling and Franziska Hoffmann
Cancers 2022, 14(17), 4342; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14174342 - 05 Sep 2022
Cited by 6 | Viewed by 2115
Abstract
Salivary gland carcinomas (SGC) are a heterogeneous group of tumors. The prognosis varies strongly according to its type, and even the distinction between benign and malign tumor is challenging. Adenoid cystic carcinoma (AdCy) is one subgroup of SGCs that is prone to late [...] Read more.
Salivary gland carcinomas (SGC) are a heterogeneous group of tumors. The prognosis varies strongly according to its type, and even the distinction between benign and malign tumor is challenging. Adenoid cystic carcinoma (AdCy) is one subgroup of SGCs that is prone to late metastasis. This makes accurate tumor subtyping an important task. Matrix-assisted laser desorption/ionization (MALDI) imaging is a label-free technique capable of providing spatially resolved information about the abundance of biomolecules according to their mass-to-charge ratio. We analyzed tissue micro arrays (TMAs) of 25 patients (including six different SGC subtypes and a healthy control group of six patients) with high mass resolution MALDI imaging using a 12-Tesla magnetic resonance mass spectrometer. The high mass resolution allowed us to accurately detect single masses, with strong contributions to each class prediction. To address the added complexity created by the high mass resolution and multiple classes, we propose a deep-learning model. We showed that our deep-learning model provides a per-class classification accuracy of greater than 80% with little preprocessing. Based on this classification, we employed methods of explainable artificial intelligence (AI) to gain further insights into the spectrometric features of AdCys. Full article
(This article belongs to the Special Issue Salivary Gland Adenoid Cystic Carcinoma)
►▼ Show Figures

Graphical abstract

12 pages, 2363 KiB  
Article
Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study
by Marta Persson, Mattias K. Andersson, Yoshitsugu Mitani, Margaret S. Brandwein-Weber, Henry F. Frierson, Jr., Christopher Moskaluk, Isabel Fonseca, Renata Ferrarotto, Werner Boecker, Thomas Loening, Adel K. El-Naggar and Göran Stenman
Cancers 2022, 14(15), 3691; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14153691 - 28 Jul 2022
Cited by 16 | Viewed by 2243
Abstract
Adenoid cystic carcinoma (ACC) is an aggressive head and neck malignancy characterized by a t (6;9) translocation resulting in an MYB–NFIB gene fusion or, more rarely, an MYBL1 fusion. The true frequency and clinical significance of these alterations are still unclear. Here, we [...] Read more.
Adenoid cystic carcinoma (ACC) is an aggressive head and neck malignancy characterized by a t (6;9) translocation resulting in an MYB–NFIB gene fusion or, more rarely, an MYBL1 fusion. The true frequency and clinical significance of these alterations are still unclear. Here, we have used tissue microarrays and analyzed 391 ACCs and 647 non-ACC salivary neoplasms to study the prevalence, expression, and clinical significance of MYB/MYBL1 alterations by FISH and immunohistochemistry. Alterations of MYB or MYBL1 were found in 78% of the cases, of which 62% had MYB alterations and 16% had MYBL1 rearrangements. Overexpression of MYB/MYBL1 oncoproteins was detected in 93% of the cases. MYB split signal, seen in 39% of the cases, was specific for ACC and not encountered in non-ACC salivary tumors. Loss of the 3′-part of MYB was enriched in grade 3 tumors and was a significant independent prognostic biomarker for overall survival in multivariate analyses. We hypothesize that loss of the 3′-part of MYB results from an unbalanced t(6;9) leading to an MYB–NFIB fusion with concomitant loss of the segment distal to the MYB breakpoint in 6q23.3. Our study provides new knowledge about the prevalence and clinical significance of MYB/MYBL1 alterations and indicates the presence of genes with tumor suppressive functions in 6q23.3-qter that contribute to poor prognosis and short overall survival in ACC. Full article
(This article belongs to the Special Issue Salivary Gland Adenoid Cystic Carcinoma)
►▼ Show Figures

Figure 1

15 pages, 2513 KiB  
Article
Development and Characterization of MYB-NFIB Fusion Expression in Adenoid Cystic Carcinoma
by Joseph O. Humtsoe, Hyun-Su Kim, Leilani Jones, James Cevallos, Philippe Boileau, Fengshen Kuo, Luc G. T. Morris and Patrick Ha
Cancers 2022, 14(9), 2263; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14092263 - 30 Apr 2022
Cited by 6 | Viewed by 2951
Abstract
Adenoid cystic carcinoma (ACC) is the second most common cancer type arising from the salivary gland. The frequent occurrence of chromosome t(6;9) translocation leading to the fusion of MYB and NFIB transcription factor genes is considered a genetic hallmark of ACC. This inter-chromosomal [...] Read more.
Adenoid cystic carcinoma (ACC) is the second most common cancer type arising from the salivary gland. The frequent occurrence of chromosome t(6;9) translocation leading to the fusion of MYB and NFIB transcription factor genes is considered a genetic hallmark of ACC. This inter-chromosomal rearrangement may encode multiple variants of functional MYB-NFIB fusion in ACC. However, the lack of an ACC model that harbors the t(6;9) translocation has limited studies on defining the potential function and implication of chimeric MYB-NFIB protein in ACC. This report aims to establish a MYB-NFIB fusion protein expressing system in ACC cells for in vitro and in vivo studies. RNA-seq data from MYB-NFIB translocation positive ACC patients’ tumors and MYB-NFIB fusion transcript in ACC patient-derived xenografts (ACCX) was analyzed to identify MYB breakpoints and their frequency of occurrence. Based on the MYB breakpoint identified, variants of MYB-NFIB fusion expression system were developed in a MYB-NFIB deficient ACC cell lines. Analysis confirmed MYB-NFIB fusion protein expression in ACC cells and ACCXs. Furthermore, recombinant MYB-NFIB fusion displayed sustained protein stability and impacted transcriptional activities of interferon-associated genes set as compared to a wild type MYB. In vivo tumor formation analysis indicated the capacity of MYB-NFIB fusion cells to grow as implanted tumors, although there were no fusion-mediated growth advantages. This expression system may be useful not only in studies to determine the functional aspects of MYB-NFIB fusion but also in evaluating effective drug response in vitro and in vivo settings. Full article
(This article belongs to the Special Issue Salivary Gland Adenoid Cystic Carcinoma)
►▼ Show Figures

Figure 1

12 pages, 3702 KiB  
Article
Patterns of Tumor Infiltrating Lymphocytes in Adenoid Cystic Carcinoma of the Head and Neck
by Johannes Doescher, Moritz Meyer, Christoph Arolt, Alexander Quaas, Jens Peter Klußmann, Philipp Wolber, Agnes Bankfalvi, Hans-Ulrich Schildhaus, Tobias Bastian, Stephan Lang, Simon Laban, Patrick J. Schuler, Cornelia Brunner, Thomas K. Hoffmann and Stephanie E. Weissinger
Cancers 2022, 14(6), 1383; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14061383 - 08 Mar 2022
Cited by 5 | Viewed by 2201
Abstract
Adenoid cystic carcinoma (ACC) is a rare malignancy in the head and neck. The prognosis remains poor and late recurrences often occur after 5 years and later. To date, there are no reliable prognostic markers for ACC. In several solid tumors, tertiary lymphoid [...] Read more.
Adenoid cystic carcinoma (ACC) is a rare malignancy in the head and neck. The prognosis remains poor and late recurrences often occur after 5 years and later. To date, there are no reliable prognostic markers for ACC. In several solid tumors, tertiary lymphoid structures (TLS) are associated with improved survival. This study aims to investigate the role of distribution patterns of tumor infiltrating immune cells (TIL) in ACC. A cohort of 50 patients from three different cancer centers was available for analysis. Sections were stained for CD3, CD4, CD8 and CD20 and evaluated with regard to their distribution of TIL. Patterns were determined as infiltrated-excluded, infiltrated-inflamed and presence of tertiary lymphoid structures. About half of the cases showed an infiltrated-excluded TIL pattern and only a minority of six cases had TLS present within the tumor. Within the inflamed phenotype CD3+ cells were by far the most abundant lymphocyte subtype, and within this compartment, CD8+ T cells were predominant. There was no influence on overall or disease-free survival by any of the TIL patterns. This indicates that ACC is a tumor with very low immunogenicity and even abundance of lymphocytes does not seem to improve prognosis for this disease. Therefore, the observed lack of response towards immunotherapy is not surprising and other methods to induce recognition of ACC by the immune system must be found. Full article
(This article belongs to the Special Issue Salivary Gland Adenoid Cystic Carcinoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

12 pages, 892 KiB  
Review
Radiation Therapy for Adenoid Cystic Carcinoma of the Head and Neck
by Carlos A. Rodriguez-Russo, Jacqueline C. Junn, Sue S. Yom and Richard L. Bakst
Cancers 2021, 13(24), 6335; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13246335 - 17 Dec 2021
Cited by 13 | Viewed by 4690
Abstract
Adenoid cystic carcinoma of the head and neck is an uncommon malignancy that can arise in the major or minor salivary glands. Perineural invasion (PNI) is an extremely frequent finding in cases of adenoid cystic carcinoma (ACC) that can be associated with significant [...] Read more.
Adenoid cystic carcinoma of the head and neck is an uncommon malignancy that can arise in the major or minor salivary glands. Perineural invasion (PNI) is an extremely frequent finding in cases of adenoid cystic carcinoma (ACC) that can be associated with significant patient morbidity and poor prognosis. By contrast, ACC rarely demonstrates lymphovascular space invasion thereby making PNI the major avenue for metastasis and a driver of treatment rationale and design. Radiotherapy is often utilized post-operatively to improve locoregional control or as a primary therapy in unresectable disease. Here we aim to review the role of radiotherapy in the management of this malignancy with a focus on target delineation and treatment regimens in the definitive, recurrent, and metastatic settings. Full article
(This article belongs to the Special Issue Salivary Gland Adenoid Cystic Carcinoma)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

19 pages, 879 KiB  
Systematic Review
PSMA PET Imaging and Therapy in Adenoid Cystic Carcinoma and Other Salivary Gland Cancers: A Systematic Review
by Boon Fei Tan, Wei Chang Colin Tan, Fu Qiang Wang, Matt Lechner, Volker Hans Schartinger, Daniel Shao Weng Tan, Kelvin Siu Hoong Loke and Wen Long Nei
Cancers 2022, 14(15), 3585; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14153585 - 22 Jul 2022
Cited by 7 | Viewed by 2196
Abstract
Adenoid cystic carcinoma (ACC) and other salivary gland cancers (SGCs) are rare tumors where application of prostate specific membrane antigen (PSMA) positron emission tomography (PET) and PSMA radioligand therapy have yet to be studied extensively. This review explores the role of PSMA PET [...] Read more.
Adenoid cystic carcinoma (ACC) and other salivary gland cancers (SGCs) are rare tumors where application of prostate specific membrane antigen (PSMA) positron emission tomography (PET) and PSMA radioligand therapy have yet to be studied extensively. This review explores the role of PSMA PET imaging and therapy as a theranostic tool for ACC and other SGCs based on current literature. A comprehensive literature search on PubMed and Embase was performed. All relevant studies containing information on PSMA PET imaging in ACC and SGC were included. Ten studies (one prospective, three retrospective, five case reports and one review paper) were included. For ACC, the mean maximum standardized uptake value (SUVmax) for local recurrence and distant metastases ranged from 2.41 to 13.8 and 2.04 to 14.9, respectively. In SGC, the meanSUVmax ranged from 1.2–12.50. Most studies observed PSMA expression positivity on immunohistochemistry (IHC) when there was PSMA PET uptake. PSMA PET was able to detect lesions not detected on standard imaging. Despite the small number of studies and wide intra-patient and inter-tumor variation of PSMA uptake in ACC and SGC, 68Gallium (68Ga)-PSMA PET has promising prospects as a diagnostic and radioligand therapeutic option. Further studies to answer the various theranostics considerations are required to guide its use in the real-world setting. Full article
(This article belongs to the Special Issue Salivary Gland Adenoid Cystic Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop